Status: Exited/Public

Tourmaline Bio

Clinical-stage company developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.

Antios Therapeutics

Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).

Jasper Therapeutics

Clinical-stage biotechnology company focused on enabling cures with hematopoietic stem cell therapies.

Merged with Amplitude Healthcare Acquisition Corporation in 2021

Caribou Biosciences

Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Completed IPO in 2021

Arch Oncology

Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.


Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Completed IPO in 2021

Sentynl Therapeutics

Commercial-stage specialty pharmaceutical company focused on pain management and adjacent specialty therapeutics areas.

Acquired by Zydus in 2017

Eyevance Pharmaceuticals

Commercial-stage specialty ophthalmic company focused on innovative and impactful branded prescription products targeting the anterior segment of the eye.

Acquired by Santen in 2020